T43.0X2A Poisoning by tricyclic and tetracyclic antidepressants, intentional self-harm, initial encounter

Name of the Condition

• Poisoning by tricyclic and tetracyclic antidepressants, intentional self-harm, initial encounter
• Technical term: T43.0X2A

Summary

This code describes an intentional self-harm poisoning by tricyclic or tetracyclic antidepressants during the initial encounter. These medications are used to treat depression and other mental health conditions. The code applies when clinical documentation specifies intentional overdose and the encounter is the first time the patient is being seen for this poisoning.

Causes

Intentional self-harm poisoning may result from deliberate ingestion of more than the prescribed dose. It can occur due to suicidal ideation or attempts, where the patient intentionally takes an overdose of the medication. The initial encounter indicates the patient is receiving care for the poisoning event for the first time.

Risk Factors

• History of depression, anxiety, or other mental health conditions that increase self-harm risk.
• Prior suicide attempts or suicidal ideation.
• Concurrent use of other medications that interact with tricyclic/tetracyclic antidepressants.
• Access to medications without supervision.
• Social or environmental stressors contributing to self-harm behavior.

Symptoms

• Drowsiness, confusion, or altered mental status.
• Rapid heart rate, irregular heartbeat, or low blood pressure.
• Seizures, tremors, or muscle rigidity.
• Nausea, vomiting, or abdominal pain.
• Dry mouth, blurred vision, or urinary retention.
• Respiratory depression or coma in severe cases.

Diagnosis

Diagnosis is based on clinical presentation, patient history, and laboratory tests. Documentation must confirm intentional self-harm and the initial encounter. Toxicology screens may identify the specific antidepressant. Physical exams assess vital signs, neurological status, and signs of overdose. Additional tests may evaluate organ function (e.g., liver, kidney) if needed.

Treatment Options

Treatment focuses on stabilizing the patient and addressing the overdose. This may include airway management, intravenous fluids, and medications to control seizures or heart rhythm. Activated charcoal may be used to reduce absorption. Psychiatric evaluation is critical for ongoing care. Supportive care, such as monitoring and symptom management, is provided as needed.

Prognosis and Follow-Up

Prognosis depends on the severity of the overdose, time to treatment, and patient factors. Early intervention improves outcomes. Follow-up care includes psychiatric evaluation, therapy, and medication management to address underlying mental health conditions. Ongoing monitoring for recurrence or complications is essential.

Complications

• Severe cardiac arrhythmias or heart failure.
• Respiratory failure requiring mechanical ventilation.
• Seizures or neurological damage.
• Kidney or liver injury from toxicity.
• Long-term mental health effects, including depression or anxiety.

Lifestyle & Prevention

• Secure storage of medications to prevent access.
• Education on proper dosing and risks of overdose.
• Regular mental health check-ins for at-risk individuals.
• Support systems for managing stress or suicidal thoughts.
• Avoiding alcohol or other drugs that interact with antidepressants.

When to Seek Professional Help

Seek immediate medical attention if intentional overdose is suspected. Signs include altered consciousness, difficulty breathing, seizures, or irregular heartbeat. Prompt care is critical to reduce complications. Follow-up with mental health providers is recommended for ongoing support.

Tips for Medical Coders

Document the intentional self-harm nature of the poisoning and confirm the initial encounter. Ensure clinical notes specify the intent (e.g., suicidal ideation, overdose attempt) and that this is the first encounter for the event. Code T43.0X2A is specific to tricyclic/tetracyclic antidepressants; verify the medication class in documentation.